Reaching the colorectal liver masses.

For most of our medical and surgical colleagues, the mere suggestion of liver surgery invokes images of yellow patients on ventilators who just barely escaped the jaws of the surgical vise and are lucky to be able to live and tell their story. Only the young and the physically strong are considered viable candidates for such a brutally heroic effort to (just) stall their cancer, and then only if they truly desire to go forward. In the minds of many, still, the balance between surviving the operation and the cancer is estimated to be a tight equilibrium. On top of that, there is a prevailing sense of having to protect these emotionally and physically friable patients from the hands of such aggressive surgeons. The modern truth could not be farther removed from these perceptions. Liver surgery has seen tremendous advances in the last decade, but some or most of these advances have hardly penetrated the medical and surgical community. Minimally invasive liver surgery, modern anesthesia techniques, novel stapler technologies, and energy devices have made liver surgery what it is nowadays: a safe and well-tolerated surgical modality with low morbidity and mortality. Complications still occur, needless to say, but with mortality rates of 1–2% in most modern series and less than 15% major morbidity, the horror images of times-gone-by hardly seem justified. The stages of colorectal cancer are based on the natural history of this disease, with stage IV disease identified as metastatic colorectal cancer. Without question, stage IV colorectal cancer carries a worse prognosis than stage III, II, or I. The natural history of stage IV colorectal cancer is dismal. However, the recognition that patients with metastatic disease may benefit greatly from resection, including liver only, lung only and even combinations of liver and lung metastases, and oligo-metastatic extrahepatic disease, has tremendously increased the overall survival of this category of stage IV colorectal cancer patients. This has not been a subtle effect; 5and 10year survival of 50–60% and 20–30% are being reported, in contrast to 0–3% 5-year survival if left untreated. These phenomenal results are not just attributable to surgery, but are the result of a multimodality approach and due to advances in chemotherapy and percutaneous interventions as well. It is hardly disputed, though, that by far the largest contribution to overall survival has been made by surgical resection where feasible. Within the hepatobiliary community, these advances are well recognized and have resulted in broad recommendations for surgical management of colorectal liver metastases. Within our highly specialized community, intense debates are raging based on the latest data and opinions regarding the validity of resection of multiple lesions in the presence of extrahepatic disease, strategies involving portal vein embolization and staged resections, as well as on ablation and resection or ablation as a primary modality. The real focus of our continued efforts, and the overall consensus, although clearly stated in our literature, may be obscured to the referring physicians counseling their patients in their offices. In fact, the debates and opinions flaring in the journals and at symposia may perpetuate to some degree the impression of bloody horror shows from which patients ought to be protected. The article by Ksienski et al. in this issue provides a rare opportunity to gain further insight into the decision-making process. All new colorectal cancer cases referred to 5 cancer centers providing comprehensive cancer care were pooled and analyzed in a prospectively maintained database. All metastatic colorectal cases were reviewed, and Society of Surgical Oncology 2010